These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24794465)

  • 1. Inhibition of Factor XI activity as a promising antithrombotic strategy.
    Chen Z; Seiffert D; Hawes B
    Drug Discov Today; 2014 Sep; 19(9):1435-9. PubMed ID: 24794465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor XI as a target for antithrombotic therapy.
    Bane CE; Gailani D
    Drug Discov Today; 2014 Sep; 19(9):1454-8. PubMed ID: 24886766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coagulation factor XI as a novel target for antithrombotic treatment.
    Löwenberg EC; Meijers JC; Monia BP; Levi M
    J Thromb Haemost; 2010 Nov; 8(11):2349-57. PubMed ID: 20727068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor XI and contact activation as targets for antithrombotic therapy.
    Gailani D; Bane CE; Gruber A
    J Thromb Haemost; 2015 Aug; 13(8):1383-95. PubMed ID: 25976012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates.
    Crosby JR; Marzec U; Revenko AS; Zhao C; Gao D; Matafonov A; Gailani D; MacLeod AR; Tucker EI; Gruber A; Hanson SR; Monia BP
    Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1670-8. PubMed ID: 23559626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial.
    Lorentz CU; Verbout NG; Wallisch M; Hagen MW; Shatzel JJ; Olson SR; Puy C; Hinds MT; McCarty OJT; Gailani D; Gruber A; Tucker EI
    Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):799-809. PubMed ID: 30700130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor XI inhibition fulfilling the optimal expectations for ideal anticoagulation.
    Székely O; Borgi M; Lip GYH
    Expert Opin Emerg Drugs; 2019 Mar; 24(1):55-61. PubMed ID: 30845846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2017 Scientific Sessions Sol Sherry Distinguished Lecture in Thrombosis: Factor XI as a Target for New Anticoagulants.
    Weitz JI; Fredenburgh JC
    Arterioscler Thromb Vasc Biol; 2018 Feb; 38(2):304-310. PubMed ID: 29269514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk.
    Zhang H; Löwenberg EC; Crosby JR; MacLeod AR; Zhao C; Gao D; Black C; Revenko AS; Meijers JC; Stroes ES; Levi M; Monia BP
    Blood; 2010 Nov; 116(22):4684-92. PubMed ID: 20807891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Congenital factor XI deficiency: an update.
    Duga S; Salomon O
    Semin Thromb Hemost; 2013 Sep; 39(6):621-31. PubMed ID: 23929304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Turning Up to Eleven: Factor XI Inhibitors as Novel Agents to Maximize Safety and Maintain Efficacy in Thromboembolic Disease.
    Cave BE; Shah SP
    Curr Probl Cardiol; 2021 Mar; 46(3):100696. PubMed ID: 32994051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hemorrhagic risk: how to evaluate it.
    Di Fusco SA; Colivicchi F; Santini M
    Pacing Clin Electrophysiol; 2013 Oct; 36(10):1191-7. PubMed ID: 23663153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa.
    Petitou M; Duchaussoy P; Herbert JM; Duc G; El Hajji M; Branellec JF; Donat F; Necciari J; Cariou R; Bouthier J; Garrigou E
    Semin Thromb Hemost; 2002 Aug; 28(4):393-402. PubMed ID: 12244487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor XI Inhibitors: Potential Role in End-Stage Kidney Disease.
    Ades M; Simard C; Vanassche T; Verhamme P; Eikelboom J; Mavrakanas TA
    Semin Nephrol; 2023 Nov; 43(6):151484. PubMed ID: 38272779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombotic and thrombolytic therapy for valvular disease: can this guideline apply to Chinese?
    Fu B; Chen H; Dong L
    Chest; 2013 May; 143(5):1513-1514. PubMed ID: 23648923
    [No Abstract]   [Full Text] [Related]  

  • 16. Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation.
    Myat A; Ahmad Y; Haldar S; Tantry US; Redwood SR; Gurbel PA; Lip GY
    Expert Rev Cardiovasc Ther; 2013 Aug; 11(8):1029-49. PubMed ID: 23984927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rivaroxaban: mode of action].
    Drouet L
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S9-15. PubMed ID: 19185786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The antithrombotic-treated patient].
    Nielsen JD; Rasmussen HM; Husted SE
    Ugeskr Laeger; 2006 Dec; 168(49):4296-9. PubMed ID: 17164056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can we IMPROVE bleeding risk assessment for acutely ill, hospitalized medical patients?
    Tay KH; Lip GY; Lane DA
    Chest; 2011 Jan; 139(1):10-3. PubMed ID: 21208874
    [No Abstract]   [Full Text] [Related]  

  • 20. Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis.
    Lip GY; Piotrponikowski P; Andreotti F; Anker SD; Filippatos G; Homma S; Morais J; Pullicino P; Rasmussen LH; Marín F; Lane DA;
    Thromb Haemost; 2012 Dec; 108(6):1009-22. PubMed ID: 23093044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.